Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sildenafil + testosterone is a combination therapy consisting of two active ingredients: sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, and testosterone, an androgen hormone. Sildenafil acts by inhibiting PDE5, leading to increased cyclic guanosine monophosphate (cGMP) levels and vasodilation in the corpus cavernosum, thereby facilitating penile erection. Testosterone supplementation is used to normalize serum testosterone levels in men with hypogonadism or low-normal testosterone, supporting sexual function and libido. This combination is primarily used in men with erectile dysfunction (ED) and suboptimal response to sildenafil monotherapy, especially those with low or low-normal testosterone. The synergistic action is based on testosterone’s role in modulating nitric oxide synthase expression and PDE5 regulation in penile tissue, potentially restoring sildenafil responsiveness in patients with inadequate testosterone status[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sildenafil + testosterone.